Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody therapy in treating patients who have advanced colorectal cancer.

Study summary:

OBJECTIVES: - Determine the toxicity, maximum tolerated dose, and pharmacokinetics of monoclonal antibody Hu3S193 in patients with advanced colorectal carcinoma. - Determine the immune response in these patients treated with this regimen. OUTLINE: This is a dose escalation study. Patients receive monoclonal antibody Hu3S193 (MAB Hu3S193) IV over 30 minutes to 4 hours weekly for 8 weeks followed by 2 weeks of rest. Patients with stable or responding disease at week 10 receive maintenance MAB Hu3S193 weekly. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of MAB Hu3S193 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 3 of 6 patients experience dose limiting toxicities. PROJECTED ACCRUAL: A total of 18-30 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically proven stage IV colorectal carcinoma - Failed or refused conventional chemotherapy - Lewis Y antigen present on more than 50% of tumor cells - Measurable or evaluable disease - No CNS tumor involvement PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 80-100% Life expectancy: - At least 6 weeks Hematopoietic: - Granulocyte count greater than 1,500/mm^3 - Platelet count greater than 100,000/mm^3 Hepatic: - Bilirubin no greater than 1.0 mg/dL - Prothrombin time less than 1.3 times control Renal: - Creatinine no greater than 1.4 mg/dL Cardiovascular: - No New York Heart Association class III or IV heart disease Other: - No serious infection requiring antibiotics or other serious illness - Not pregnant or nursing - No history of bleeding gastric ulcers or pancreatitis - No diabetes mellitus requiring insulin - Human antimouse antibody (HAMA) negative PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior mouse monoclonal antibody or antibody fragments - At least 4 weeks since other prior immunotherapy Chemotherapy: - See Disease Characteristics - At least 4 weeks since prior chemotherapy Endocrine therapy: - No concurrent steroids or other antiinflammatory agents Radiotherapy: - At least 4 weeks since prior radiotherapy Surgery: - Not specified



Primary Contact:

Study Chair
Sydney Welt, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10021
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.